Angiogenesis inhibitors for patients with ovarian cancer: A meta-analysis of 12 randomized controlled trials

Current Medical Research and Opinion

Volumn 32, Issue 3, 2016, Pages 555-562

  Li, Xuyuan ^a   Zhu, Sujuan ^b   Hong, Chaoqun ^b   Cai, Haoquan ^c  

^a SHANTOU CENTRAL HOSPITAL   (China)

^b CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Angiogenesis; Meta analysis; Ovarian cancer; Toxicity

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CEDIRANIB; NINTEDANIB; PAZOPANIB; SORAFENIB; TREBANANIB; PROTEIN KINASE INHIBITOR;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER FATIGUE; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COCHRANE LIBRARY; DATA EXTRACTION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ERUPTION; EDEMA; EMBASE; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HOARSENESS; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LIVER TOXICITY; MEDLINE; META ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEINURIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS; UNSPECIFIED SIDE EFFECT; WOUND HEALING; DISEASE FREE SURVIVAL; FEMALE; OVARIAN NEOPLASMS;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84959234927     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1131152     Document Type: Article

References (25)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
2. Pecorelli S, Favalli G, Gadducci A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol 2009;27:4642-8
3. Hope JM, Blank SV. Current status of maintenance therapy for advanced ovarian cancer. Int J Womens Health 2010;1:173-80
4. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365:2473-83
5. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96
6. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30:2039-45
7. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32:1302-8
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-34
9. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-17
10. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16 1-8
11. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. ESMO 2013;38:abstract 10
12. du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: A Randomized Placebo-Controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/-nintedanib for advanced ovarian cancer. Int J Gynecol Cancer 2013;23(8 Suppl):7-8
13. Herzog TJ, Scambia G, Kim B-G, et al. A randomized phase II trial of maintenance therapy with sorafenib in front-line ovarian carcinoma. Gynecol Oncol 2013;130:25-30
14. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebocontrolled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 2011;30:362-71
15. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebocontrolled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011;29:3798-804
16. Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): A randomised, open-label, phase 2 trial. Lancet Oncol 2015;16:561-8
17. Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2014;15: 799-808
18. du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014;32:3374-82
19. Mei L, Chen H, Wei DM, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database Syst Rev 2013;6:CD007414
20. Kümler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 2014;40:960-73
21. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172-83
22. Backen A, Renehan AG, Clamp AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumabtreated patients with ovarian cancer. Clin Cancer Res 2014;20:4549-58
23. Chan JK, Kiet TK, Blansit K, et al. MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer. Gynecol Oncol 2014;133: 568-74
24. Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: A panel of potential biomarkers informing treatment selection. Clin Cancer Res 2013;19:5227-39
25. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13:724-33